{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:02:18Z","timestamp":1791259338561,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00431-011-1606-3","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T05:14:41Z","timestamp":1319778881000},"page":"181-188","source":"Crossref","is-referenced-by-count":91,"title":["The role of enzyme replacement therapy in severe Hunter syndrome\u2014an expert panel consensus"],"prefix":"10.1007","volume":"171","author":[{"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Bodamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun Schulze","family":"Frenking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ver\u00f3nica Mu\u00f1oz","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,29]]},"reference":[{"key":"1606_CR1","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","volume":"70","author":"G Bach","year":"1973","unstructured":"Bach G, Eisenberg F Jr, Cantz M, Neufeld EF (1973) The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A 70:2134\u20132138","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1606_CR2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","volume":"31","author":"S Bagewadi","year":"2008","unstructured":"Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE (2008) Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis 31:733\u2013737","journal-title":"J Inherit Metab Dis"},{"key":"1606_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA, HOS investigators (2010) Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II\u2014data from the Hunter Outcome Survey. Mol Genet Metab 101:123\u2013129","journal-title":"Mol Genet Metab"},{"key":"1606_CR4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","volume":"97","author":"BK Burton","year":"2009","unstructured":"Burton BK, Wiesman C, Paras A, Kim K, Katz R (2009) Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses. Mol Genet Metab 97:234\u2013236","journal-title":"Mol Genet Metab"},{"key":"1606_CR5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jpeds.2007.10.015","volume":"152","author":"DJ Coman","year":"2008","unstructured":"Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB (2008) Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. J Pediatr 152:723\u2013727","journal-title":"J Pediatr"},{"key":"1606_CR6","doi-asserted-by":"crossref","unstructured":"Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D (2006) A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess 10:iii-iv, ix-113","DOI":"10.3310\/hta10200"},{"key":"1606_CR7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1399-0004.1998.tb02746.x","volume":"53","author":"R Froissart","year":"1998","unstructured":"Froissart R, Maire I, Millat G, Cudry S, Birot AM, Bonnet V, Bouton O, Bozon D (1998) Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients. Clin Genet 53:362\u2013368","journal-title":"Clin Genet"},{"key":"1606_CR8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmg.2008.02.005","volume":"51","author":"E Galan-Gomez","year":"2008","unstructured":"Galan-Gomez E, Guerrero-Rico A, Caceres-Marzal C, Zambrano-Castano M, Moreno-Tejero ML, Grande-Tejada AM, Fernandez-Hernandez S, Vaquerizo-Madrid J, Cardesa-Garcia JJ (2008) Early response to idursulfase treatment in a 3-year-old boy affected of Hunter syndrome. Eur J Med Genet 51:268\u2013271","journal-title":"Eur J Med Genet"},{"key":"1606_CR9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10545-011-9280-1","volume":"34","author":"E Glamuzina","year":"2011","unstructured":"Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L, Vellodi A (2011) Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis 34:749\u2013754","journal-title":"J Inherit Metab Dis"},{"key":"1606_CR10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/(SICI)1098-1004(1996)7:1<76::AID-HUMU14>3.0.CO;2-P","volume":"7","author":"SL Goldenfum","year":"1996","unstructured":"Goldenfum SL, Young E, Michelakakis H, Tsagarakis S, Winchester B (1996) Mutation analysis in 20 patients with Hunter disease. Hum Mutat 7:76\u201378","journal-title":"Hum Mutat"},{"key":"1606_CR11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","volume":"154","author":"N Guffon","year":"2009","unstructured":"Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R (2009) Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17\u00a0years. J Pediatr 154:733\u2013737","journal-title":"J Pediatr"},{"key":"1606_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","volume":"94","author":"P Harmatz","year":"2008","unstructured":"Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94:469\u2013475","journal-title":"Mol Genet Metab"},{"key":"1606_CR13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1023\/A:1005363414792","volume":"21","author":"K Isogai","year":"1998","unstructured":"Isogai K, Sukegawa K, Tomatsu S, Fukao T, Song XQ, Yamada Y, Fukuda S, Orii T, Kondo N (1998) Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese patients with mucopolysaccharidosis type II (Hunter disease). J Inherit Metab Dis 21:60\u201370","journal-title":"J Inherit Metab Dis"},{"key":"1606_CR14","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ymgme.2007.10.059","volume":"93","author":"R Katz","year":"2008","unstructured":"Katz R, Burton B (2008) A home infusion protocol for MPS II patients on enzyme replacement therapy (ERT). Mol Genet Metab 93:S25\u2013S26","journal-title":"Mol Genet Metab"},{"key":"1606_CR15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99\u2013109","journal-title":"Neurology"},{"key":"1606_CR16","first-page":"21","volume":"36","author":"P Li","year":"1999","unstructured":"Li P, Bellows AB, Thompson JN (1999) Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J Med Genet 36:21\u201327","journal-title":"J Med Genet"},{"key":"1606_CR17","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","volume":"121","author":"R Martin","year":"2008","unstructured":"Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, Muenzer J (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121:e377\u2013e386","journal-title":"Pediatrics"},{"key":"1606_CR18","unstructured":"McGill J, Sillence D, Ketteridge D, Peters H, Knight G (2008) Guidelines for eligibility to receive treatment for mucopolysaccharidosis type II (MPS-II) with idursulfase through the life saving drugs program. Australian Government Department of Health and Ageing Web site. Available at http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/lsdp-info\/#Idursulfase Accessed 20 April 2011"},{"key":"1606_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-3476(96)70202-0","volume":"129","author":"EJ McKinnis","year":"1996","unstructured":"McKinnis EJ, Sulzbacher S, Rutledge JC, Sanders J, Scott CR (1996) Bone marrow transplantation in Hunter syndrome. J Pediatr 129:145\u2013148","journal-title":"J Pediatr"},{"key":"1606_CR20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A (2006) Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 15:330\u2013333","journal-title":"Br J Nurs"},{"key":"1606_CR21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00019053-200725030-00003","volume":"25","author":"DF Moore","year":"2007","unstructured":"Moore DF, Ries M, Forget EL, Schiffmann R (2007) Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry\u2013Anderson disease. PharmacoEconomics 25:201\u2013208","journal-title":"PharmacoEconomics"},{"key":"1606_CR22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1034\/j.1399-0004.2001.600412.x","volume":"60","author":"I Moreira da Silva","year":"2001","unstructured":"Moreira da Silva I, Froissart R, Marques dos Santos H, Caseiro C, Maire I, Bozon D (2001) Molecular basis of mucopolysaccharidosis type II in Portugal: identification of four novel mutations. Clin Genet 60:316\u2013318","journal-title":"Clin Genet"},{"key":"1606_CR23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0065-3101(24)00309-8","volume":"33","author":"J Muenzer","year":"1986","unstructured":"Muenzer J (1986) Mucopolysaccharidoses. Adv Pediatr 33:269\u2013302","journal-title":"Adv Pediatr"},{"key":"1606_CR24","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","volume":"124","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, Link B, Martin RA, Molter DW, Munoz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E (2009) Multidisciplinary management of Hunter syndrome. Pediatrics 124:e1228\u2013e1239","journal-title":"Pediatrics"},{"key":"1606_CR25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga A, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A (2006) A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465\u2013473","journal-title":"Genet Med"},{"key":"1606_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA (2009) Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123:19\u201329","journal-title":"Pediatrics"},{"key":"1606_CR27","first-page":"3421","volume-title":"The metabolic and molecular bases of inherited disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421\u20133452","edition":"8"},{"key":"1606_CR28","unstructured":"Paras A, Katz R, Burton BK (2007) Challenges of treating patients with Hunter syndrome and CNS disease with enzyme replacement therapy (ERT): a case report. ASHG 2007 Meeting Poster Presentation Listings. Available at http:\/\/www.ashg.org\/genetics\/ashg07s\/f20104.htm . Accessed 20 April 2011"},{"key":"1606_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2009.10.008","volume":"47","author":"VK Prasad","year":"2010","unstructured":"Prasad VK, Kurtzberg J (2010) Transplant outcomes in mucopolysaccharidoses. Semin Hematol 47:59\u201369","journal-title":"Semin Hematol"},{"key":"1606_CR30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/03007990902892633","volume":"25","author":"M Schlander","year":"2009","unstructured":"Schlander M, Beck M (2009) Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 25:1285\u20131293","journal-title":"Curr Med Res Opin"},{"key":"1606_CR31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","volume":"350","author":"SL Staba","year":"2004","unstructured":"Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, Allison-Thacker J, Wood S, Wenger DA, Rubinstein P, Hopwood JJ, Krivit W, Kurtzberg J (2004) Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350:1960\u20131969","journal-title":"N Engl J Med"},{"key":"1606_CR32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/adc.79.3.237","volume":"79","author":"E Vafiadaki","year":"1998","unstructured":"Vafiadaki E, Cooper A, Heptinstall LE, Hatton CE, Thornley M, Wraith JE (1998) Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch Dis Child 79:237\u2013241","journal-title":"Arch Dis Child"},{"key":"1606_CR33","first-page":"93","volume":"34","author":"J Aerde van","year":"1981","unstructured":"van Aerde J, Plets C, Van der Hauwaert L (1981) Hydrocephalus in Hunter syndrome. Acta Paediatr Belg 34:93\u201396","journal-title":"Acta Paediatr Belg"},{"key":"1606_CR34","unstructured":"Vellodi A, Wraith JE, Cleary MA, Ramaswami U, Lavery C, Jessop E (2007) Guidelines for the investigation and management of mucopolysaccharidosis type II. National Commissioning Group For Highly Specialised Services Web site. Available at http:\/\/www.specialisedservices.nhs.uk\/library\/23\/Guidelines_for_Mucopolysaccharidosis_Type_II.pdf Accessed 20 April 2011"},{"key":"1606_CR35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","volume":"22","author":"A Vellodi","year":"1999","unstructured":"Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE (1999) Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22:638\u2013648","journal-title":"J Inherit Metab Dis"},{"key":"1606_CR36","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, Kakkis ED, Guffon N (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5\u00a0years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase). Pediatrics 120:e37\u2013e46","journal-title":"Pediatrics"},{"key":"1606_CR37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267\u2013277","journal-title":"Eur J Pediatr"},{"key":"1606_CR38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jmg.14.6.445","volume":"14","author":"S Yatziv","year":"1977","unstructured":"Yatziv S, Epstein CJ (1977) Hunter syndrome presenting as macrocephaly and hydrocephalus. J Med Genet 14:445\u2013447","journal-title":"J Med Genet"},{"key":"1606_CR39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2214.1981.tb00838.x","volume":"7","author":"ID Young","year":"1981","unstructured":"Young ID, Harper PS (1981) Psychosocial problems in Hunter's syndrome. Child Care Health Dev 7:201\u2013209","journal-title":"Child Care Health Dev"},{"key":"1606_CR40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/adc.57.11.828","volume":"57","author":"ID Young","year":"1982","unstructured":"Young ID, Harper PS (1982) Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child 57:828\u2013836","journal-title":"Arch Dis Child"},{"key":"1606_CR41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","volume":"25","author":"ID Young","year":"1983","unstructured":"Young ID, Harper PS (1983) The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 25:481\u2013489","journal-title":"Dev Med Child Neurol"},{"key":"1606_CR42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","volume":"19","author":"ID Young","year":"1982","unstructured":"Young ID, Harper PS, Newcombe RG, Archer IM (1982) A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet 19:408\u2013411","journal-title":"J Med Genet"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00431-011-1606-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T06:32:26Z","timestamp":1713076346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-011-1606-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s00431-011-1606-3","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,29]]}}}